Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.48 – $1.74
Volume2,486
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.49M
Price / earnings
—
Price / book
0.79×
Price / sales
1.59×
EV / sales
-1.06×
EV / EBITDA
0.5×
Profitability
Earnings per share
-$1.56
Return on assets
-57.94%
Return on equity
-82.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.15×
Quick ratio
3.15×
Cash ratio
3.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XBIO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$725.26K
$660.6K
$806.92K
$0
$1.03M
$589.9K
$593.26K
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$725.26K
$660.6K
$806.92K
$0
$1.03M
$589.9K
$593.26K
$0
Selling, general and administrative
$1.94M
$1.08M
$647.6K
$615.91K
$815.21K
$657.75K
$656.64K
$705.71K
Research and development
$520.66K
$552.01K
$661.44K
$773.42K
$756.48K
$656.56K
$879.03K
$1.04M
Total operating expenses
$2.46M
$1.63M
$1.31M
$1.39M
$1.57M
$1.31M
$1.54M
$1.75M
Operating income
-$1.74M
-$971.69K
-$502.12K
-$1.39M
-$544.73K
-$724.41K
-$942.41K
-$1.75M
Interest expense
$0
$0
$0
-$104.21K
$0
$0
$0
-$197.99K
Income before taxes
-$1.7M
-$929.7K
-$456.38K
-$579.08K
-$509.94K
-$688.7K
-$903.14K
-$1.05M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.7M
-$929.7K
-$456.38K
-$579.08K
-$509.94K
-$688.7K
-$903.14K
-$1.05M
Net income attributable to common shareholders
-$1.7M
-$929.7K
-$456.38K
-$579.08K
-$509.94K
-$688.7K
-$903.14K
-$1.05M
EBITDA
-$1.74M
-$971.69K
-$502.12K
-$1.39M
-$544.73K
-$724.41K
-$942.41K
-$1.75M
Basic earnings per share
-$0.72
-$0.41
-$0.20
-$0.27
-$0.33
-$0.45
-$0.59
-$0.68
Diluted earnings per share
-$0.72
-$0.41
-$0.20
-$0.27
-$0.33
-$0.45
-$0.59
-$0.68
Recent news
Company coverage with links to the original publishers.
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ: XBIO) from Buy to Neutral, citing pending clinical path visibility.
In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
Xenetic announced a one-for-ten reverse stock split, the second ...Full story available on Benzinga.com
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.